DiA Secured $14M Investment Round to Accelerate Availability of its Ultrasound AI solutions

DiAs technology enables clinicians of all skills and experience levels to automatically and seamlessly analyze ultrasound images and identify clinical abnormalities DiA Imaging Analysis, a leading provider of advanced AI-based solutions for ultrasound analysis, today announced that the company has closed on a $14 million in additional investment led by a consortium of new and existing international investors. Additionally, the company will pursue new and expanded partnerships with ultrasound vendors, PACS/Healthcare IT companies, resellers, and distributors while continuing to grow its global presence in Asia, Europe, and the U.S. DiA’s AI-based technology imitates the way the human eye detects borders and identifies motion, allowing clinicians of all levels of experience to capture the right ultrasound images and automatically identify clinical abnormalities that are otherwise difficult to find visually. With a total of $25 million in funding, the company has experienced great momentum in commercializing its technology and bringing LVivo toolbox to hospitals, clinics, and clinicians around the world. With cardiac damage being one of the most common and serious impacts of the virus, the company’s technology has been used extensively near bedside and remotely to quickly detect abnormalities in both the left and right ventricle and expedite care to those in need. Having served as SonoSite’s (Fujifilm company) Chief Medical Officer for nearly 15 years, Dr. Mandavia is recognized as an expert and thought leader in point-of-care ultrasound technologies.